194 related articles for article (PubMed ID: 37339176)
41. Prevention of tumor growth driven by PIK3CA and HPV oncogenes by targeting mTOR signaling with metformin in oral squamous carcinomas expressing OCT3.
Madera D; Vitale-Cross L; Martin D; Schneider A; Molinolo AA; Gangane N; Carey TE; McHugh JB; Komarck CM; Walline HM; William WN; Seethala RR; Ferris RL; Gutkind JS
Cancer Prev Res (Phila); 2015 Mar; 8(3):197-207. PubMed ID: 25681087
[TBL] [Abstract][Full Text] [Related]
42. Copy number amplification of the PIK3CA gene is associated with poor prognosis in non-lymph node metastatic head and neck squamous cell carcinoma.
Suda T; Hama T; Kondo S; Yuza Y; Yoshikawa M; Urashima M; Kato T; Moriyama H
BMC Cancer; 2012 Sep; 12():416. PubMed ID: 22994622
[TBL] [Abstract][Full Text] [Related]
43. The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas.
Anderson RT; Keysar SB; Bowles DW; Glogowska MJ; Astling DP; Morton JJ; Le P; Umpierrez A; Eagles-Soukup J; Gan GN; Vogler BW; Sehrt D; Takimoto SM; Aisner DL; Wilhelm F; Frederick BA; Varella-Garcia M; Tan AC; Jimeno A
Mol Cancer Ther; 2013 Oct; 12(10):1994-2005. PubMed ID: 23873848
[TBL] [Abstract][Full Text] [Related]
44. HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.
Hah JH; Zhao M; Pickering CR; Frederick MJ; Andrews GA; Jasser SA; Fooshee DR; Milas ZL; Galer C; Sano D; William WN; Kim E; Heymach J; Byers LA; Papadimitrakopoulou V; Myers JN
Head Neck; 2014 Nov; 36(11):1547-54. PubMed ID: 24123531
[TBL] [Abstract][Full Text] [Related]
45. A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma.
Mazumdar T; Byers LA; Ng PK; Mills GB; Peng S; Diao L; Fan YH; Stemke-Hale K; Heymach JV; Myers JN; Glisson BS; Johnson FM
Mol Cancer Ther; 2014 Nov; 13(11):2738-50. PubMed ID: 25193510
[TBL] [Abstract][Full Text] [Related]
46. PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer.
Herzog A; Bian Y; Vander Broek R; Hall B; Coupar J; Cheng H; Sowers AL; Cook JD; Mitchell JB; Chen Z; Kulkarni AB; Van Waes C
Clin Cancer Res; 2013 Jul; 19(14):3808-19. PubMed ID: 23640975
[TBL] [Abstract][Full Text] [Related]
47. mTOR inhibition as an adjuvant therapy in a metastatic model of HPV+ HNSCC.
Coppock JD; Vermeer PD; Vermeer DW; Lee KM; Miskimins WK; Spanos WC; Lee JH
Oncotarget; 2016 Apr; 7(17):24228-41. PubMed ID: 27015118
[TBL] [Abstract][Full Text] [Related]
48. Bosutinib Inhibits EGFR Activation in Head and Neck Cancer.
Segrelles C; Contreras D; Navarro EM; Gutiérrez-Muñoz C; García-Escudero R; Paramio JM; Lorz C
Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29933569
[TBL] [Abstract][Full Text] [Related]
49. Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial.
Day TA; Shirai K; O'Brien PE; Matheus MG; Godwin K; Sood AJ; Kompelli A; Vick JA; Martin D; Vitale-Cross L; Callejas-Varela JL; Wang Z; Wu X; Harismendy O; Molinolo AA; Lippman SM; Van Waes C; Szabo E; Gutkind JS
Clin Cancer Res; 2019 Feb; 25(4):1156-1164. PubMed ID: 30420444
[TBL] [Abstract][Full Text] [Related]
50. AKT3 is a key regulator of head and neck squamous cell carcinoma.
Takahashi H; Rokudai S; Kawabata-Iwakawa R; Sakakura K; Oyama T; Nishiyama M; Chikamatsu K
Cancer Sci; 2021 Jun; 112(6):2325-2334. PubMed ID: 33811778
[TBL] [Abstract][Full Text] [Related]
51. Comprehensive Genomic Profiling of Patient-matched Head and Neck Cancer Cells: A Preclinical Pipeline for Metastatic and Recurrent Disease.
Nisa L; Barras D; Medová M; Aebersold DM; Medo M; Poliaková M; Koch J; Bojaxhiu B; Eliçin O; Dettmer MS; Angelino P; Giger R; Borner U; Caversaccio MD; Carey TE; Ho L; McKee TA; Delorenzi M; Zimmer Y
Mol Cancer Res; 2018 Dec; 16(12):1912-1926. PubMed ID: 30108165
[TBL] [Abstract][Full Text] [Related]
52. A Phase 1b Study of Cetuximab and BYL719 (Alpelisib) Concurrent with Intensity Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma.
Dunn LA; Riaz N; Fury MG; McBride SM; Michel L; Lee NY; Sherman EJ; Baxi SS; Haque SS; Katabi N; Wong RJ; Xiao H; Ho AL; Pfister DG
Int J Radiat Oncol Biol Phys; 2020 Mar; 106(3):564-570. PubMed ID: 31678634
[TBL] [Abstract][Full Text] [Related]
53. A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.
Jimeno A; Shirai K; Choi M; Laskin J; Kochenderfer M; Spira A; Cline-Burkhardt V; Winquist E; Hausman D; Walker L; Cohen RB
Ann Oncol; 2015 Mar; 26(3):556-61. PubMed ID: 25524478
[TBL] [Abstract][Full Text] [Related]
54. Efficacy of axitinib in metastatic head and neck cancer with novel radiographic response criteria.
Swiecicki PL; Bellile EL; Brummel CV; Brenner JC; Worden FP
Cancer; 2021 Jan; 127(2):219-228. PubMed ID: 33079405
[TBL] [Abstract][Full Text] [Related]
55. β1 integrin mediates unresponsiveness to PI3Kα inhibition for radiochemosensitization of 3D HNSCC models.
Korovina I; Elser M; Borodins O; Seifert M; Willers H; Cordes N
Biomed Pharmacother; 2024 Feb; 171():116217. PubMed ID: 38286037
[TBL] [Abstract][Full Text] [Related]
56. Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial.
Keam B; Hong MH; Shin SH; Heo SG; Kim JE; Ahn HK; Lee YG; Park KU; Yun T; Lee KW; Kim SB; Lee SC; Kim MK; Cho SH; Oh SY; Park SG; Hwang S; Nam BH; Kim S; Kim HR; Yun HJ;
J Clin Oncol; 2024 Feb; 42(5):507-517. PubMed ID: 37699162
[TBL] [Abstract][Full Text] [Related]
57. A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Lee JH; Heo SG; Ahn BC; Hong MH; Cho BC; Lim SM; Kim HR
Cancer Med; 2021 Oct; 10(20):7012-7020. PubMed ID: 34528763
[TBL] [Abstract][Full Text] [Related]
58. Role of EphB3 Receptor in Mediating Head and Neck Tumor Growth, Cell Migration, and Response to PI3K Inhibitor.
Bhatia S; Griego A; Lennon S; Oweida A; Sharma J; Rohmer C; Uyanga N; Bukkapatnam S; Van Court B; Raben D; Young C; Heasley L; Karam SD
Mol Cancer Ther; 2018 Sep; 17(9):2049-2059. PubMed ID: 29970482
[TBL] [Abstract][Full Text] [Related]
59. Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer.
Patel V; Marsh CA; Dorsam RT; Mikelis CM; Masedunskas A; Amornphimoltham P; Nathan CA; Singh B; Weigert R; Molinolo AA; Gutkind JS
Cancer Res; 2011 Nov; 71(22):7103-12. PubMed ID: 21975930
[TBL] [Abstract][Full Text] [Related]
60. Targeting PI3K/AKT/mTOR Signaling Pathway as a Radiosensitization in Head and Neck Squamous Cell Carcinomas.
Su YC; Lee WC; Wang CC; Yeh SA; Chen WH; Chen PJ
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]